U.S., April 18 -- ClinicalTrials.gov registry received information related to the study (NCT07535645) titled 'Baricitinib for Post-HSCT Persistent Thrombocytopenia' on April 06.
Brief Summary: This is a prospective, open-label phase 1b/2 clinical trial to explore the safety and efficacy profiles of baricitinib in patients with thrombopoietin-receptor-agonist-refractory persistent thrombocytopenia after allogeneic hematopoietic stem cell transplantation.
Study Start Date: April 15
Study Type: INTERVENTIONAL
Condition:
Persistent Thrombocytopenia
Allogeneic Hematopoietic Stem Cell Transplantation
Intervention:
DRUG: Baricitinib
Baricitinib, an orally administered, selective, reversible JAK1/2 inhibitor.
Recruitment Status: NOT_YET_RE...